Adoptive cell therapy with young T cells
First Claim
Patent Images
1. A method of generating a T cell infusion product for promoting regression of a cancer in a mammal, the method comprising:
- (i) culturing autologous T cells;
(ii) enriching the cultured T cells for CD8+ T cells;
(iii) expanding the number of cultured T cells using OKT3 antibody, IL-2, and feeder lymphocytes to provide an expanded number of T cells that are about 19 to about 35 days old; and
(iv) providing the expanded number of T cells that are about 19 to about 35 days old as a cell infusion product,wherein (ii) is performed prior to (iii), the T cells have not been screened for specific tumor reactivity, and the T cells recognize an antigen of a cancer.
0 Assignments
0 Petitions
Accused Products
Abstract
The invention provides a method of promoting regression of a cancer in a mammal comprising (i) culturing autologous T cells; (ii) expanding the cultured T cells; (iii) administering to the mammal nonmyeloablative lymphodepleting chemotherapy; and (iv) after administering nonmyeloablative lymphodepleting chemotherapy, administering to the mammal the expanded T cells, wherein the T cells administered to the mammal are about 19 to about 35 days old and have not been screened for specific tumor reactivity, whereupon the regression of the cancer in the mammal is promoted.
91 Citations
11 Claims
-
1. A method of generating a T cell infusion product for promoting regression of a cancer in a mammal, the method comprising:
-
(i) culturing autologous T cells; (ii) enriching the cultured T cells for CD8+ T cells; (iii) expanding the number of cultured T cells using OKT3 antibody, IL-2, and feeder lymphocytes to provide an expanded number of T cells that are about 19 to about 35 days old; and (iv) providing the expanded number of T cells that are about 19 to about 35 days old as a cell infusion product, wherein (ii) is performed prior to (iii), the T cells have not been screened for specific tumor reactivity, and the T cells recognize an antigen of a cancer. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11)
-
Specification